News Summary: Generic rivals hurt Merck results

Published



BAD NEWS: First-quarter sales and net income for Merck & Co. both plunged — 9 percent and 8 percent, respectively — as the world’s third-largest drugmaker got slammed by generic competition to multiple drugs. It cut its earnings forecast, sending shares down 3 percent in unusually heavy trading.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.